10-K/A: SBC Medical Group Holdings Files Amended 10-K, Updates Executive Team and Corporate Governance

SBC Medical Group Holdings files an amendment to its 2024 annual report to include previously omitted information on directors, executive compensation, and corporate governance, while also updating details on a new executive employment agreement.

Summary

• SBC Medical Group Holdings filed Amendment No. 1 on Form 10-K/A to its 2024 Annual Report on Form 10-K to include information required by Items 10 through 14 of Part III.
• The amendment restates Items 10, 11, 12, 13, and 14 of Part III of the 2024 10-K in their entirety.
• The cover page of the 2024 10-K is amended to update the number of outstanding shares of common stock as of April 15, 2025, which is 103,611,251 after deducting 270,000 shares of treasury stock.
• Item 9B (Other Information) is amended to include information regarding a new executive employment agreement with Miki (Shimizu) Yamazaki, who will serve as the Company's Chief Strategy Officer.
• The amendment updates the exhibit list to include new certifications by the principal executive officer and principal financial officer under Section 302 of the Sarbanes-Oxley Act of 2002.
• The company's board of directors consists of five members: Yoshiyuki Aikawa, Yuya Yoshida, Ken Edahiro, Mike Sayama, and Fumitoshi Fujiwara.
• Ken Edahiro, Mike Sayama, and Fumitoshi Fujiwara are considered independent directors.
• The company has established an audit committee, a compensation committee, and a nominating and corporate governance committee.
• The company's executive compensation program is designed to attract, motivate, incentivize, and retain employees at the executive level.
• The company's stockholders approved the SBC Medical Group Holdings Incorporated Equity Incentive Plan on August 23, 2024, reserving 15,000,000 shares of common stock for equity awards.
• The company has entered into employment agreements with Dr. Yoshiyuki Aikawa, Yuya Yoshida, Ryoji Murata, Akira Komatsu, and Miki (Shimizu) Yamazaki.
• The company is a controlled company because Dr. Yoshiyuki Aikawa controls approximately 89.23% of the voting power of the outstanding common stock.

Sentiment

Score: 6

Explanation: The document is primarily factual, reporting on an amendment to a filing and changes in personnel and governance. There are some potential negatives related to related party transactions and the company's controlled status, but overall the sentiment is neutral.

Positives

• The company has a well-defined executive compensation program designed to align executive interests with those of stockholders.
• The establishment of an equity incentive plan allows the company to offer equity-based awards to attract and retain key personnel.
• The board of directors includes independent members, ensuring oversight and governance.
• The company has established audit, compensation, and nominating and corporate governance committees to oversee key functions.
• The company is providing consulting services to medical corporations, which may generate revenue.

Negatives

• The company is a controlled company, which may reduce the protections afforded to minority shareholders.
• Related party transactions are significant, potentially raising concerns about conflicts of interest.
• The CEO's relatives being members of the MCs could create potential conflicts of interest.
• The company disposed of Kijima and Skynet to entities owned by the CEO for cash, which may raise questions about the fairness of the transactions.

Risks

• The company's reliance on related party transactions could pose risks if these relationships are not managed appropriately.
• The non-compete and non-solicitation provisions in the executive employment agreements may not be fully enforceable due to varying state laws.
• The company's status as a controlled company could lead to less stringent corporate governance practices.
• The potential for accelerated vesting of awards due to a change in control could result in parachute payments that are non-deductible and subject to excise tax.

Future Outlook

The company is pursuing a long-term growth strategy aimed at expanding and stabilizing its business foundation by creating an environment that can better facilitate the establishment of new clinics by MCs.

Management Comments

• The Board believes that its leadership structure currently serves the best interests of our shareholders, partners, customers, and other stakeholders because of Dr. Aikawas deep expertise in the Companys business.

Industry Context

The document does not provide specific details on how this announcement relates to broader industry trends or competitors, but it does mention the challenging competitive environment and the company's strategy to expand and stabilize its business foundation.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or comparable companies.
• Without specific benchmarks, it's difficult to assess the company's performance against industry peers.

Management Changes

Corporate Governance

Related Party Transactions

• The company has significant related party transactions with various medical corporations (MCs) and other entities related to the CEO and other key personnel.
• These transactions include revenue from services provided to MCs, accounts receivable and payable balances, finance lease receivables, and long-term investments in MCs.
• The company purchased medical equipment and cosmetics from Japan Medical & Beauty Inc., a related party, for $8,472,202 in 2024 and $2,842,588 in 2023.
• The company disposed of Kijima and Skynet to entities owned by the CEO for cash consideration.

Stakeholder Impact

• Shareholders: The amendment provides updated information on the company's governance and executive compensation, which may influence investor sentiment.
• Employees: The appointment of a new Chief Strategy Officer and the implementation of an equity incentive plan may impact employee morale and motivation.
• Customers: Changes in the company's service offerings and clinic operations could affect customer experience.
• Suppliers: Related party transactions with suppliers may raise questions about fairness and transparency.
• Creditors: The company's financial relationships with related parties could impact its creditworthiness.

Next Steps

• The company will continue to implement its long-term growth strategy.
• The company will continue to monitor and manage related party transactions.
• The company will file a registration statement on Form S-8 covering the common stock issuable under the Plan.

Key Dates

Keywords

executive compensation, corporate governance, related party transactions, equity incentive plan, independent directors, controlled company, financial reporting, SBC Medical Group, directors, 10-K/A